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Abstract
Background—Monitoring of HIV viral load in patients on combination antiretroviral therapy
(ART) is not generally available in resource-limited settings. We examined the cost-effectiveness
of qualitative point-of-care viral load tests (POC-VL) in sub-Saharan Africa.
Design—Mathematical model based on longitudinal data from the Gugulethu and Khayelitsha
township ART programmes in Cape Town, South Africa.
Methods—Cohorts of patients on ART monitored by POC-VL, CD4 cell count or clinically were
simulated. Scenario A considered the more accurate detection of treatment failure with POC-VL
only, Scenario B also considered the effect on HIV transmission. Scenario C further assumed that
the risk of virologic failure is halved with POC-VL due to improved adherence. We estimated the
change in costs per quality-adjusted life-year gained (incremental cost-effectiveness ratios, ICER)
of POC-VL compared to CD4 and clinical monitoring.
Results—POC-VL tests with detection limits <1000 copies/ml increased costs due to
unnecessary switches to second-line ART, without improving survival. Assuming POC-VL unit
costs between US$5–US$20 and detection limits between 1000 and 10000 copies/ml, the ICER of
POC-VL was US$4010–US$9230 compared to clinical and US$5960–US$25540 compared to
CD4 monitoring. In Scenario B the corresponding ICERs were US$2450–US$5830 and US
$2230–US$10380. In Scenario C the ICER ranged between US$960–US$2500 compared to
clinical monitoring and between cost-saving and US$2460 compared to CD4 monitoring.
Conclusions—The cost-effectiveness of POC-VL for monitoring ART is improved by a higher
detection limit, by taking the reduction in new HIV infections into account and when assuming
that failure of first-line ART is reduced due to targeted adherence counselling.
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Introduction
Despite the rapid scale-up of combination antiretroviral therapy (ART) in HIV-infected
patients during the past decade, the capacity to monitor treatment response remains limited
in many settings [1]. Routine viral load (VL) monitoring is standard to detect virologic
failure and inform decisions on switching patients to second-line ART in industrialised
countries. In contrast, in most resource-limited settings these decisions are based on clinical
symptoms and CD4 cell counts, which correlate poorly with VL [2]. The main barriers for
the implementation of VL monitoring in low-income settings are the need for centralised
laboratory facilities [3] and the required scale-up of expensive second-line ART [4].
A recent randomised controlled trial (RCT) evaluating the effect of routine laboratory
monitoring on clinical outcomes among patients on ART in Uganda showed that compared
to clinical monitoring alone outcomes were more favourable with laboratory monitoring, but
there was no significant difference between the CD4 arm and the VL arm [5]. The setting of
an RCT may not, however, reflect routine care in settings without access to VL monitoring,
where patients may stay on failing first-line regimens for prolonged periods of time, which
may increase the risk of onward transmission of HIV [6], lead to multi-drug resistance [7]
and increase mortality [8]. Lack of VL monitoring hampers the detection of poor adherence
to ART and the targeted counselling of patients [9]. Finally, a substantial number of patients
may switch unnecessarily with suppressed VL [10].
In sub-Saharan Africa only South Africa [11] and Botswana [12] have implemented VL
monitoring in their national ART programmes. Point-of-care (POC) tests are being
developed for monitoring both CD4 cell counts and VL. UNITAID and the Bill & Melinda
Gates Foundation are supporting the development and implementation of POC tests [13, 14].
POC testing can improve the monitoring of ART by making results available rapidly and
providing access to clinics in remote settings [13].
The aim of our study was to explore the cost-effectiveness of routine POC-VL monitoring in
settings in sub-Saharan Africa where only CD4 or clinical monitoring is currently available.
We assumed that the VL test would be qualitative and available to all patients on ART. We
varied the assumptions regarding the costs and detection limits of the test, and the costs of
second-line therapy.
Methods
Data sources
The International epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-
SA) is a collaboration of ART programmes in seven countries in Southern Africa [15]. Data
are collected at ART initiation (baseline) and each follow-up visit using standardised
instruments. All sites have ethical approval to collect data and participate in IeDEA-SA. We
restricted our analyses to the Gugulethu [16] and Khayelitsha [17] township ART
programmes in Cape Town, South Africa, where VL and CD4 cell counts are measured
regularly (Table 1). All treatment-naïve patients aged at least 16 years, who had started ART
with at least two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside
reverse transcriptase inhibitor (NNRTI) were included. Second-line ART was defined as a
switch from an NNRTI-based regimen to a protease inhibitor-based regimen, with at least
one NRTI changed.
Definitions of treatment failure
Criteria for clinical and immunologic failure were those of the World Health Organization
(WHO) [18]. Virologic failure was defined with five alternative thresholds (125, 400, 1000,
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5000 or 10000 copies/ml). Failures have to be confirmed in a second measurement within
one year (usually 3 months after the first measurement). True treatment failure was defined
as a rebound in VL after suppression to at least 125 copies/ml, with VL remaining elevated
until the patient switches therapy. Whereas virologic, immunologic and clinical failures are
observations, true treatment failure is an underlying event which cannot be observed exactly.
Detectable VL of unknown origin (DVU) was defined as VL above 125 copies/ml, which
returns below 125 copies/ml while on the same regimen. We calculated the probabilities of
observing a DVU with all five thresholds (Supplementary Table 1).
Mathematical model
The IeDEA-SA mathematical model of ART has been described in detail elsewhere [6]. We
adapted this model to compare quality-adjusted life-years (QALYs), costs and cost-
effectiveness between different monitoring strategies in cohorts of patients receiving ART.
In brief, the model simulates cohorts of patients who are followed from starting ART until
death. The properties of the individual patient and the timing of events are calculated
probabilistically based on a series of rules and parametric distributions [6]. The model was
parameterised with data from the South African township ART programmes and estimates
published in the literature (Supplementary Table 2). For the present study we additionally
modelled VL trajectories (Web Appendix 1).
Each simulated patient is at risk of true treatment failure, clinical failure, immunologic
failure and death. The observation of the failures depends on the chosen monitoring strategy.
If VL monitoring is available, virologic failure is observed if the VL trajectory is above the
limit of detection (LOD) at the time of the measurement. Virologic failure may also be
observed if the trajectory is below the LOD but DVU is present, typically due to blips [19,
20] or non-adherence. After an immunologic or virologic failure is observed, another
measurement is taken 3 months later. If failure is observed again, the patient switches to
second-line ART. On second-line ART the patient continues to be at risk of failure. Finally,
the number of expected HIV transmissions is calculated. Each patient is assigned a
frequency of partner change and sex acts. The times of virologic failures and switching
determine the value of the VL at each sex act. The expected number of new infections is
calculated using a relationship between VL and infectiousness based on the results of the
Rakai study in Uganda [21, 22] (Web Appendix 2).
Costs, QALYs and ICERs
Costs of appointments, CD4 and VL measurements and ART were considered
(Supplementary Table 3). Cost estimates of the antiretroviral drugs were based on the
ceiling price list of the Clinton Health Access Initiative (CHAI) [23]. We used the average
of the two most common first-line (zidovudine/lamivudine/nevirapine or tenofovir/
lamivudine/efavirenz, $146.50/year) and second-line (zidovudine or tenofovir/lamivudine/
ritonavir-boosted lopinavir, $465.50/year) regimens. Based on discussions with experts and
organisations developing and implementing POC-VL tests, a range of prices per test were
assumed. With the currently available laboratory-based VL tests, the cost of the
consumables is about US$28 and the cost of the machine between US$100000 and US
$225000 [13]. The cost-effectiveness study [24] of the Ugandan trial [5] estimated the total
cost per test to be US$29.64, but higher estimates have also been reported [25, 26]. The Bill
& Melinda Gates Foundation is currently funding the development of a qualitative POC-VL
test costing US$3 to US$5 per cartridge and <US$1000 per machine [14]. We assumed that
a plausible minimum for the unit cost of the POC-VL test (including consumables and per-
test costs of the machine) would be US$5 with a LOD of 1000 copies/ml or higher. For
lower thresholds, we assumed a minimum of US$10 per test. Finally, we assumed that the
cost would not exceed US$20 per test for any LOD.
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Quality of life weights were derived from the disability weights according to the Global
Burden of Disease project [27]. For asymptomatic HIV, the weight was 0.865. For
symptomatic HIV, we took the weight of the most common disease, TB, and multiplied it
with the weight of asymptomatic HIV: 0.865*0.729=0.631. We used the same weights for
all patients irrespective of age. We also estimated costs and lost QALYs in the partners
infected by the modelled patients. We assumed that the infected partners would have a life
expectancy of 40 years at the time of infection, which would be reduced to 30 years because
of HIV. We calculated incremental cost-effectiveness ratios (ICER), which are defined as
the ratio of the change in costs divided by the change in QALYs. Both QALYs and costs
were discounted by 3% per year.
Model scenarios
The following monitoring strategies were modelled: clinical monitoring, 6-monthly CD4
count monitoring and 6-monthly VL monitoring with a qualitative POC-VL test with a LOD
of 125, 400, 1000, 5000 or 10000 copies/ml. We assumed that the results of the VL test
would be immediately available to the caregiver and the patient. We used the model to
calculate the ICERs of VL monitoring with different LODs compared to either CD4 cell
count or clinical monitoring. We investigated three possible benefits of routine VL
monitoring: in Scenario A we included only the more accurate detection of treatment failure
and more timely and potentially more appropriate switching of patients to second-line ART.
In Scenario B we additionally considered the effect on HIV transmission. In Scenario C we
also assumed that the risk of virologic failure is twice as high with clinical or CD4
monitoring than with VL monitoring, because VL monitoring detects non-adherence and
improves adherence by making targeted interventions possible [28, 29].
Results
We present key model outcomes, including the number of unnecessary switches to second-
line ART, the number of missed true treatment failures, the QALYs expected at the start of
ART, the costs of patient management on ART (in total and broken down by costs of
appointments, tests and ART), and outcomes related to HIV transmission (QALYs lost due
to new infections and total costs due to new infections). These outcomes are given in Table
2 per lifetime of one patient or 100 patients on ART, by monitoring strategy and the five
different LODs for the POC-VL test.
Five to six out of 100 true treatment failures remained unobserved over the entire lifetime
with VL monitoring strategies, compared to 37 with CD4 and 76 with clinical monitoring.
The number of unnecessary switches to second-line ART per 100 patients was 9 with
clinical monitoring and 5 with CD4 count monitoring. With VL monitoring it ranged from
15 (lowest LOD, 125 copies/ml) to 5 or fewer (LODs ≥1000 copies/ml). Despite these
differences in the accuracy of monitoring and switching, only small differences in the
quality-adjusted life expectancy emerged, with mean QALYs expected at the start of ART
ranging from 12.78 with clinical monitoring to 12.93 with POC-VL monitoring. Expressed
per 100 patients, the difference in QALYs was 15. If we assumed that the true treatment
failure rate was twice as high with clinical monitoring compared to VL monitoring (Scenario
C), this difference increased to 33 QALYs. Depending on the monitoring strategy, the
number of new HIV infections ranged from around 4 with POC-VL monitoring to 7 per 100
patients with clinical monitoring, leading to a loss of 15 to 23 QALYs per 100 patients
(Table 2). The number of new infections was higher in VL monitoring with LOD 125
copies/ml compared to higher LODs. This is due to the large number of unnecessary
switches to second-line ART, which will move second-line failure forward in time and, in
the absence of further treatment options, increase the total number of patients on failing
regimens.
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Total (lifetime) cost of ART ranged between US$3037 per patient (clinical monitoring) and
US$4739 per patient (VL monitoring, US$20/VL test, LOD 125 copies/ml). The most
important determinant of total costs was second-line ART, which increased over three-fold
from US$456 per patient (clinical monitoring) to US$1506 per patient (VL monitoring,
LOD 125 copies/ml) (Figure 1). The costs of tests were substantially higher in strategies
with VL monitoring compared to CD4 monitoring even when assuming a low unit cost of
US$5 per VL test. New HIV infections caused additional costs between US$9400 (VL
monitoring, LOD 1000 or 5000 copies/ml) and US$14500 (clinical monitoring) per 100
patients on ART (Table 2) but were not an important contributor to costs over the lifetime of
the index patients on ART (Figure 1). Since VL monitoring using a LOD of 125 or 400
copies/ml was more expensive, did not improve survival and caused slightly more
transmissions compared to VL monitoring with a higher LOD, these two strategies were
excluded from the cost-effectiveness analyses.
The cost-effectiveness of POC-VL monitoring compared to CD4 monitoring was poor in
Scenario A (Table 3): even the most cost-effective VL monitoring scenario (US$5 per POC-
VL test, LOD 10000 copies/ml) had an incremental cost-effectiveness ratio (ICER) of US
$5960 per QALY. Compared to clinical monitoring, CD4 count monitoring (ICER US
$3300/QALY) was more cost-effective than VL monitoring (ICER US$4010 per QALY)
under the same assumptions (US$5/test, LOD 10000 copies/ml). Including the effect on
transmission (Scenario B) improved the cost-effectiveness of routine VL monitoring.
Compared to CD4 count monitoring, the ICER of routine VL monitoring with the same
assumptions as above decreased from US$5960 under Scenario A to US$2230 per QALY.
Compared to clinical monitoring, POC-VL monitoring became more cost-effective than
CD4 count monitoring (US$2450/QALY versus US$2590/QALY). Finally, in Scenario C
routine POC-VL monitoring became a clearly cost-effective strategy. Compared to CD4
count monitoring, VL monitoring was cost-saving if the cost of the VL test was US$5. The
ICER compared to either CD4 or clinical monitoring remained below US$2500 per QALY
with all LODs and costs of POC-VL tests.
Figure 2 shows the cost-effectiveness of POC-VL monitoring compared to CD4 monitoring
(left panel) and clinical monitoring (right panel) for Scenarios A, B and C. The LOD was
1000 copies/ml and the costs of POC-VL tests and of second-line ART ranged from US$5 to
US$50 and US$150 to US$500, respectively. The limits for cost-effectiveness (3 times per-
capita gross domestic product) are shown for three sub-Saharan African countries: Zambia
(US$4242/QALY), Mozambique (US$1749/QALY) and Malawi (US$1053/QALY) [30]. In
Scenarios A and B the cost-effectiveness of routine VL monitoring was highly sensitive to
the cost of second-line therapy: the lower the cost of the second-line therapy, the more cost-
effective VL monitoring was. In Scenario C, the cost of the POC-VL test was the most
important determinant when comparing with CD4 count monitoring whereas the cost of
second-line ART was again the determining factor in the comparison with clinical
monitoring (Figure 2).
In Scenario A, VL monitoring could be considered cost-effective in Zambia if both VL and
second-line costs were minimised. In Scenario B, cost-effectiveness in Mozambique could
be reached under the same conditions. The pattern changed in Scenario C when VL
monitoring was compared to CD4 monitoring: since VL monitoring now decreased the need
for second-line therapy, cost-effectiveness increased with higher second-line therapy costs.
Assuming a fixed price of US$500 per year for second-line therapy (corresponding to
current levels), a unit cost of US$12 per VL test would render VL monitoring cost-effective
in Malawi. A unit cost of US$5 would be cost-saving.
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Discussion
This mathematical modelling study found that POC-VL monitoring likely improves survival
slightly and prevents new HIV infections, but also increases the costs of ART. VL
monitoring more accurately detects treatment failure, but since the risk of failure is low, the
resulting benefit on survival was small. The cost-effectiveness was thus poor when, in
Scenario A, we only considered this benefit of POC-VL monitoring. When we also included
effects on adherence and HIV transmission, our estimates of cost-effectiveness improved.
Nevertheless, POC-VL monitoring remained more expensive than CD4 cell monitoring even
when reducing the costs of POC tests to US$5, since in most scenarios VL monitoring
increased the need for second-line ART and required additional tests to confirm failure. To
minimise unnecessary switches to second-line ART, the LOD of the POC-VL test should be
1000 copies/ml or higher.
We studied the cost-effectiveness of POC-VL monitoring under a range of assumptions with
results covering a wide range of ICERs from cost-saving to over US$25000/QALY saved.
We did not highlight any particular scenario, since the key determinants, i.e. the unit cost of
the POC-VL test and the overall benefit of VL monitoring, remain unknown. The assumed
benefits in Scenarios B and C will also vary across different settings. In particular, the effect
on HIV transmission will depend on the sexual behaviour, and the effect on adherence on
the type of adherence intervention in place in a given programme.
Our study consistently supports the use of VL tests with detection limits of 1000 copies/ml
or above. This is at odds with current practice: a systematic review found that out of 39
studies from sub-Saharan Africa reporting a single virologic failure threshold, only two used
10000 copies/ml as recommended by WHO at that time [31], and 12 used a threshold of 500
copies/ml or below [32]. Since then, WHO reduced the threshold from 10000 to 5000
copies/ml [18]. Using a threshold below 1000 copies/ml is problematic because it results in a
large number of DVUs. Additional measurements are required to determine if a detectable
VL has returned to undetectable levels before switching to second-line ART. Moreover,
some patients will have two consecutive DVUs and therefore switch to second-line therapy
unnecessarily.
The cost-effectiveness of routine VL compared to CD4 monitoring has been investigated in
several modelling studies [25, 26, 33–37] as well as a randomised controlled trial [5]
(Supplementary Table 4). The results from these studies vary and are difficult to compare
because monitoring frequency, failure criteria, time horizon, costs and other parameters
differed substantially between studies. Only Phillips et al modelled adherence [35], and
Vijayaraghavan et al was the only study considering HIV transmission [34]. Moreover, this
study, together with the recent analysis by Hamers et al [26], were the only two studies that
replaced VL monitoring with CD4 monitoring, rather than combining them. The results of
Hamers et al were clearly in favour of VL monitoring: the ICER was $86 per life-year when
compared to CD4 monitoring. However, Hamers et al investigated a laboratory-based,
quantitative VL test and assumed 100% sensitivity and specificity. We found that the poor
specificity with low LODs led to many unnecessary switches. We feel that a specificity of
100% is unrealistic even with a quantitative test, and that the high cost-effectiveness
reported by Hamers et al is questionable.
Our study has several limitations. The lack of empirical data on the effect of VL monitoring
on adherence and consequently the rate of virologic failure is one of them. In the
Khayelitsha and Gugulethu township cohorts less than 5% of all patients failed virologically
in the first year of ART. We assumed that without VL monitoring failure rates would be
twice as high. Some support for a higher rate of virologic failure in the absence of VL
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monitoring comes from cross-sectional studies of virologic failure from settings without
routine VL monitoring. For example, in the HIV/AIDS outpatient clinic of the Central
Hospital in Yaoundé, Cameroon, the percentage of patients with detectable VL at one year
was 16% [38]. Similarly, 26% of individuals receiving ART in Luanda, Angola had
detectable VL after a median of one year of follow up [39]. In a rural district of Malawi,
13% of patients on ART had detectable VL at 10 months [40]. In all three studies virologic
failure was defined as a VL above 1000 copies/ml. However, the key question – to what
extent routine VL monitoring prevents treatment failure – remains unanswered. More
research is urgently needed to address this question.
Another limitation is the lack of data on long-term outcomes: simulations were not limited
to a fixed time window, but modelled costs and benefits over the entire lifespan. We thus
had to extrapolate the progression of the disease from the available data, which was
restricted to, at most, 10 years of follow-up. Our results may therefore be sensitive to long-
term outcomes, although their influence on model outcomes was reduced by annual
discounting. Also, the data on disease progression from the two township ART programmes
in Cape Town, which have electronic medical records and access to routine VL and CD4
monitoring and second-line ART, may not be applicable to other settings in sub-Saharan
Africa. We did not explicitly model all potential benefits of POC-VL testing, for example
improved retention in care [41] or the prevention of viral resistance. The effect on adherence
was modelled by varying virologic failure rates but costs of adherence interventions were
not included. Finally, our estimates of new infections do not take into account transmission
dynamics at the population level or differences in risk behaviours. We will expand the
present model to address these shortcomings.
Conclusions
Our study demonstrates that the impact of POC-VL monitoring on adherence and HIV
transmission remains poorly understood despite the fact that these are the key factors that
determine whether or not POC-VL tests will be cost-effective. To minimise unnecessary
switches, the detection limit of the test should not be less than 1000 copies/ml, which has
important implications for the design of these tests. In general, lowering the cost of any
POC-VL test, and of second-line ART regimens, are the most promising strategies to
maximise cost-effectiveness of monitoring ART with POC-VL tests.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Breakdown of costs of antiretroviral therapy care per patient in different monitoring
strategies
Unit cost of viral load test was assumed to be US$10.
ART, antiretroviral therapy
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Figure 2. Cost-effectiveness of point-of-care routine viral load monitoring compared to CD4 (left
panel) or clinical monitoring (right panel) as a function of the unit cost of a viral load test and
the annual costs of second-line antiretroviral therapy in three scenarios: A (equal failure rates,
no transmission), B (equal failure rates, transmission included) and C (failure rate 2× higher
with clinical or CD4 monitoring compared to viral load monitoring, transmission included)
Limit of detection of the viral load test was assumed to be 1 000 copies/ml. The black lines
show the maximum limit of cost-effectiveness (3× per-capita gross domestic product) for
selected southern African countries.
ART, antiretroviral therapy; QALY, quality adjusted life years
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Table 1
Patient characteristics in the Gugulethu and Khayelitsha programmes used to
parameterise the mathematical model
A total of 9888 patients were followed for 16278 person-years on first-line therapy and 435 person-years on
second-line therapy.
Unit Value
Age at baseline* (n=9888) Years, median (IQR) 33 (29–39)
Gender (n=9888) Number (percentage)
 Male 3240 (32.8%)
 Female 6648 (67.2%)
Cohort (n=9888) Number (percentage)
 Gugulethu 2658 (26.9%)
 Khayelitsha 7230 (73.1%)
CD4 cell count at baseline* (n=7259) Cells/μl; median (IQR) 93 (41–158)
HIV-1 viral load at baseline* (n=5274) Log10 copies/ml; median (IQR) 5.0 (4.5–5.5)
First-line regimens (n=9888) Number (percentage)
 d4T 3TC EFV 4985 (50.4%)
 d4T 3TC NVP 3182 (32.2%)
 ZDV 3TC NVP 1031 (10.4%)
 ZDV 3TC EFV 680 (6.9%)
 d4T ddI EFV 7 (0.1%)
 ZDV ddI EFV 3 (0.0%)
Second-line regimens (n=353) Number (percentage)
 ZDV ddI LPV/r 244 (69.1%)
 ZDV 3TC EFV LPV/r 34 (9.6%)
 d4T ddI LPV/r 22 (6.2%)
 ZDV 3TC LPV/r 9 (2.6%)
 Other 44 (12.5%)
Follow-up time on ART (n=9888) Months, median (IQR) 17.8 (7.5–29.8)
Time from ART start to switch to 2nd-line (n=353) Months, median (IQR) 21.2 (13.7–30.3)
IQR, interquartile range; 3TC, lamivudine; d4T, stavudine; ZDV, zidovudine; ddI, didanosine; NVP, nevirapine; EFV, efavirenz; LPV/r, ritonavir-
boosted lopinavir.
*Baseline variables were defined as the closest value within 3 months before up to 2 weeks after antiretroviral therapy initiation.
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